Vnitr Lek 2023, 69(3):156-165 | DOI: 10.36290/vnl.2023.028

Multimorbidity in nephrotic syndrome

Vladimír Teplan1, 2
1 Interní a kardiologická klinika Fakultní nemocnice Ostrava a Lékařská fakulta Ostravské univerzity, Ostrava
2 Subkatedra nefrologie, Institut postgraduálního vzdělávání ve zdravotnictví, Praha

Nephrotic syndrome (NS) is characterized by high proteinuria (over 3,5g/24 hrs), hypalbuminaemia, general edemas and hypercoagulation. Beside of primary glomerulonephritides this is found in secundary glomerulopaties eg. diabetes, systemic inflammatory diseases, oncology, damage by drugs and poisoning, by alergy, serious infections and in children from hereditary reasons. The most frequent reason for NS in adults patiens is diabetes and diabetes with nephropathy represents almost 40% of dialysed patiens. From this point of view, there is great interest focusing on gliflozins (SGLT2 inhibitors) with positive nephroprotecive effect. It leads do increasing of glycosuria with concomitant natriuresis and osmotic diuresis. The effect is proportional to glomerulal filtration, but the effect on natriuresis stay in all stages of renal insufficiency.

Keywords: nephrotic syndrome, primary and secundary glomeruolopaties, diabetes, gliflozins.

Accepted: April 27, 2023; Published: May 16, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Teplan V. Multimorbidity in nephrotic syndrome. Vnitr Lek. 2023;69(3):156-165. doi: 10.36290/vnl.2023.028.
Download citation

References

  1. Teplan V, et al. Praktická nefrologie, Grada Publishing, Praha. 2006.
  2. Wang CS,Greenbaum LA. Nephrotic syndrome.Pediatr Clin North Am. 2019;66(1):73-85. Go to original source...
  3. Downie ML, Gallibois C,Parekh RS, Noone DG.Nephrotic syndrome in intants and childre: pathyophysiology and management.Paediatr Int Child Health. 2017;37(4):248-258. Go to original source...
  4. Václavík J. Dyslipidemia and hypertension - what to worry about more? Vnitř Lék. Spring 2018;(4):395-401. Go to original source...
  5. Politano SA,Colbert GB,Hamiduzzaman N. Nephrotic syndrome. Prim Care. 2020;47(4):597-613. Go to original source...
  6. Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018;392(10):61-74. Go to original source...
  7. Saleem MA. Molecular stratification of idiopathic nephrotic syndrome. Nat Rev Nephrol. 2019;15(12):750-765. Go to original source... Go to PubMed...
  8. Kodnesr C. Diagnosis and management of nephrotic syndrome in adults. AmFamPhysician. 2016;93(6):479-485.
  9. Siddall EC, Radhakrishan J. The pathophysiology of edema formation in the nephrotic syndrome. Kidney Int. 2012;82(6):635-642. Go to original source... Go to PubMed...
  10. Teplan V. Nefrotický syndrom, in V. Teplan a kol. Metabolismus a ledviny Grada Avicenum Praha 2000:249-255.
  11. Iijima K, Sako M, Nozu P. Rituximab for nephrotic syndrome in childre. Clin Exp Nephrol. 20187;21(2):193-202. Go to original source...
  12. Meena J, Bagga A. Current perspectives in management of edema in nephrotic syndrome.Indian J Pediatr. 2022;87(8):633-640. Go to original source...
  13. Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechamisms and consequences. Kidney Int. 2016;90(1):41-52. Go to original source... Go to PubMed...
  14. Seigneux S, Martin PY. Management of patients with nephrotic syndrome. Swiss Med Wkly. 2009;139(29-30):410-422.
  15. Rovin BH,Adler SG,Barrat J, et al.Executive summary of the KDIGO 2021 for management of glomerular disease. Kidney Int 2021;100: 753-779 Go to original source... Go to PubMed...
  16. Hoorn EJ, Ellison DH. Diuretic resistence. Am J Kidney, DiS. 2017;69(1):136-142. Go to original source...
  17. Duffy M, Jain S, Harrel N, et al. Albumin and Furosemide Combination for management of edema in nephrotic syndrome : a review of clinical studies. Cells. 2015;4:622-630. Go to original source... Go to PubMed...
  18. Derebail VK, Rheault MN, Kerlin BA. Role of direct anticoagulants in patients with kidney disease. Kidney Int. 2020;97(4):664-675. Go to original source... Go to PubMed...
  19. Teplan V,Mengerová O. Dieta a nutriční opatření u chorob ledvin a močových cest. Mladá fronta ed. Aesculap, Praha 2010.
  20. Stoycheff N, Stevens LA,Schmid C, et al. Nephrotic syndrome in diabetic kidney disease : an evaluation and update of the definition.Am J Kidney, DiS. 2009;54(5):840-849. Go to original source...
  21. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487-493. Go to original source...
  22. Ceriello A, Prattichizzo F, Phillip M, Hirsch IB, Mathieu C, Battelino T. Glycaemic management in diabetes: old and new approaches. Lancet Diabetes Endocrinol. 2022;10(1):75-84. Go to original source... Go to PubMed...
  23. de Boer IH, Caramori ML, Chan JCN, et al. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence‑based advances in monitoring and treatment. Kidney Int. 2020;98:839-848. Go to original source... Go to PubMed...
  24. Neuen BL, Jardine MJ, Perkovic V. Sodium‑glucose cotransporter 2 inhibition: which patient with chronic kidney should be treated in the future? Nephrol Dial Transplant. 2020;35:i48-i55. Go to original source...
  25. Imai T, Akimoto T, Ito C, et al. Management of diabetes associated with nephrotic syndrome : therapeutic potential of dapagliflozin for protracted volume retention. Drug Target Insights. 2015;9:29-31. Go to original source... Go to PubMed...
  26. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(4):323-334. Go to original source...
  27. van Bommel EJM,Muskiet MHA,Tonneijick L et al. SGLT2 inhibition in the diabetic kidney - from mechanism to clinical outcome.Cli j Am Soc Nephrol. 2017;12(4):700-710. Go to original source...
  28. Perkovic V, Jardine MJ, Neal B, et al. CREDENCE Trial Ivestigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. Go to original source...
  29. Heerspink HJL, Stefansson BV,Correa‑Rottwe J, et al. Dapagliflozin in patients with chronic kidnery disease.N Engl j Med. 2020;383(15):1436-1446. Go to original source...
  30. Zavačová D, Václavík J. SGLT2 inhibiotors - a new pillar for the treatment of heart failure. Vnitř Lék. 2021;67(8):475-478. Go to original source...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.